Novo Nordisk
NVOleaderNovo Nordisk is the global leader in diabetes care and has become a GLP-1 giant with Ozempic and Wegovy. The obesity-drug revolution has made it Europe's most valuable company. Its near-monopoly on injectable semaglutide positions it at the center of the $100B+ weight-loss drug market.
Products & Revenue
Product Revenue Share
Revenue Breakdown ($42.6B)
Static data (loading live financials…)
Segment Breakdown & Key Customers
Product Details
GLP-1 receptor agonist for type 2 diabetes
GLP-1 agonist approved for chronic weight management
First oral GLP-1 for type 2 diabetes
Long-acting and rapid-acting insulin products
Hemophilia treatments (NovoSeven, Esperoct)
Supply Chain Relationships
Macro & Market Context
GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
Upcoming Catalysts
Supply Chain Issues
덴마크·미국·프랑스 3개 공장 증설 완료로 Wegovy 공급 부족 해소. 2026Q2부터 대기 처방 소화 본격화.
주1회 경구 복합제 Amycretin 3상 진입. 체중감소 효과 Wegovy 대비 +5%p 기대, 2028년 허가 목표.
Institutional Signals
| Institution | Action | Value | Quarter | Filing Date |
|---|---|---|---|---|
| BlackRock | reducing | $163K | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $200M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $23M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $649K | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $8M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $59M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $2M | 2024.06 | 2024-08-13↓ |
| BlackRock | accumulating | $487M | 2024.06 | 2024-08-13↑ |
| BlackRock | reducing | $2M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $314K | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $7M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $41M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $3M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $3M | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $228K | 2024.06 | 2024-08-13↓ |
| BlackRock | reducing | $24M | 2024.06 | 2024-08-13↓ |
| State Street | accumulating | $306M | 2025.12 | 2026-02-13↑ |
| FMR (Fidelity) | accumulating | $182M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | reducing | $23K | 2025.12 | 2026-02-17↓ |
| FMR (Fidelity) | accumulating | $254M | 2025.12 | 2026-02-17↑ |
| FMR (Fidelity) | reducing | $16M | 2025.12 | 2026-02-17↓ |
| FMR (Fidelity) | accumulating | $58M | 2025.12 | 2026-02-17↑ |
Institutional Ownership
13F basis · Q4 2025| Institution | Change | Ownership % | Prev. Quarter | Shares | Value | SEC |
|---|---|---|---|---|---|---|
| Capital Group | Maintained | 1.80% | — | 92.0M shares | $4,200M | 13F |
| Wellington | Increased | 0.69% | — | 35.0M shares | $1,600M | 13F |
| Baillie Gifford | Maintained | 0.52% | — | 26.0M shares | $1,200M | 13F |
| Fidelity Contrafund | Increased | 0.47% | — | 24.0M shares | $1,100M | 13F |
Latest News
AI Analysis
Click "Get AI Analysis" for an AI-powered supply chain analysis of Novo Nordisk.
Company Info
News Gap Score
IB Activity
84
Media Score
62
Cascade Position
Role in Cascade
first follower
Typical Delay
0-1 trading days
Novo Nordisk and Lilly form a GLP-1 duopoly; positive class data lifts both, while competitive data creates relative winners and losers.
View Full CascadeSector Overview — 제약 / 바이오
Sector NewsGLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집
GLP-1 시장 규모 (2030E)
mRNA 암백신 임상 성공률
AI 신약개발 단계
PFE/MRNA 52주 변화
Key Themes
- •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
- •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
- •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성
Upcoming Catalysts
- ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
- ◆MRNA 암백신 FDA BLA 제출 예정